Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide.
Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod.
A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic.
Multiple sclerosis and pain.
Health-related quality of life and disease-modifying treatment behaviour in relapsing-remitting multiple sclerosis - a multicentre cohort study.
Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US.
Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial.
Plasma chemerin levels in patients with multiple sclerosis.
An evidence-based review of natalizumab therapy in the management of Crohn's disease.
Stelara (Ustekinumab) receives FDA Approval for Treatment of Moderate to Severe Plaque Psoriasis with Four-Times-A-Year Maintenance Dosing
Suppression of Brain Mast Cells Degranulation Inhibits Microglial Activation and Central Nervous System Inflammation.
[Epstein-Barr virus in the pathogenesis of multiple sclerosis (a review).]
Smoking induces long-lasting effects through a monoamine-oxidase epigenetic regulation.
Endogeneous Remyelination: Findings in Human Studies.
Evaluation of a new approach for semi-automatic segmentation of the cerebellum in patients with multiple sclerosis.
Serum and CSF measles antibody levels increase over time in patients with multiple sclerosis or clinically isolated syndrome.
Including known covariates can reduce power to detect genetic effects in case-control studies.
Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment.
Genetics of primary progressive multiple sclerosis.
Early Treatment with Anti-VLA-4 mAb Can Prevent the Infiltration and/or Development of Pathogenic CD11b+CD4+ T Cells in the CNS during Progressive EAE.
The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study.
Suppression of Experimental Autoimmune Optic Neuritis by the Novel Agent Fingolimod.
Impact of cerebrospinal-fluid oligoclonal immunoglobulin bands and HLA-DRB1 risk alleles on brain magnetic-resonance-imaging lesion load in Swedish multiple sclerosis patients.
Do not treat from CIS onset: evaluate disease course and prognosis first - No (treat!).
Conference Report: Multiple Sclerosis Update: Hot topics from 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS).

Pages